Evidence map›Paper›PMID 39611711›Full record

ArticleFuture oncology (London, England)2025

Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.

Ashton Hunt, Daria Ditri, Ankit Chadha, Georgina Keogh, Jack Thompson, Will Loughborough, Iain McNeish, Jonathan Krell, Jacqueline McDermott, Laura Tookman and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ashton HuntDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.ORCID 0009-0003-4166-1358
Daria DitriDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.ORCID 0009-0006-5504-0992
Ankit ChadhaDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Georgina KeoghDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Jack ThompsonDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Will LoughboroughDepartment of Radiology, Royal Hospitals Bath, Bath, UK.
Iain McNeishDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Jonathan KrellDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Jacqueline McDermottDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Laura TookmanDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.
Sadaf Ghaem-MaghamiDepartment of Gynaecological Oncology, Imperial College Healthcare NHS Trust, London, UK.ORCID 0000-0002-7369-5080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTesting for tumor BRCA mutations and homologous recombination deficiency (HRD) is recommended for all patients with advanced high-grade epithelial ovarian cancer. Delays in the HRD testing process can significantly affect the treatment offered to patients.

methodsHRD testing pathways and sampling processes were analyzed for tests sent from a tertiary gynae-oncology referral center between December 2020 and January 2023.

resultsA total of 148 hRD tests were performed in 125 patients. The overall success rate of HRD testing was 69.6%. The success rates of obtaining results were: from diagnostic image-guided biopsy 66.7% (

conclusionsBy optimizing the factors affecting HRD test success, we can obtain faster results and offer patients appropriate treatment at earlier time points to improve patient outcomes.

Indexed as

Carcinoma, Ovarian EpithelialGenetic TestingHomologous RecombinationOvarian NeoplasmsAdultAgedAged, 80 and overBRCA1 ProteinBRCA2 ProteinFemaleHumansMiddle AgedMutationNeoplasm GradingRetrospective StudiesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1BRCA2genetic mutationgenomic testingHRDOvarian cancerPARPi

Identifiers

PMID39611711
PMCPMC11792859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.